Novartis AG
Real-time prices from Yahoo Finance's public feed. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All NVS news ›Arcus Biosciences, Inc. (RCUS)
Stock Price, News, Quote & History Yahoo! Finance Canada Oops, something went wrong Arcus Biosciences, Inc. (RCUS) Arcus Biosciences, Inc. Overview Biotechnology / Healthcare Arcus Biosciences, Inc., a clinical-stage biopharmaceutical…
Hikma Pharmaceuticals PLC (HIK.L)
stock price, news, quote and history Yahoo Finance UK Hikma Pharmaceuticals PLC (HIK.L) Hikma Pharmaceuticals PLC Overview Drug Manufacturers - Specialty & Generic / Healthcare Hikma Pharmaceuticals PLC develops, manufactures, markets, and…
MedinCell Halts Euronext Trading Ahead of Market-Sensitive Announcement
An update from MedinCell SA ( (FR:MEDCL) ) is now available. MedinCell SA requested and obtained a temporary suspension of trading in its shares on Euronext Paris from 9:00 a.m. CEST, ahead of a scheduled company announcement, with trading…
Corcept Therapeutics Inc (HTD.DU) Stock Forum & Discussion
Yahoo! Finance Canada Oops, something went wrong Corcept Therapeutics Inc (HTD.DU) - NVLH.NE NEVADA LITHIUM RESOURCES INC 0.0400 -0.0350 (-46.67%) - BULL.CN Quest Critical Metals Inc. 0.0150 -0.0050 (-25.00%) - NVLH.V Nevada Lithium…
AstraZeneca (LSE:AZN) Puts AI Into Biologics Labs With New Discovery Tie Up
AstraZeneca (LSE:AZN) has launched a new AI-driven biologics discovery collaboration with Carterra, announced ahead of trading on 9 October 2026. The project focuses on large molecule biologics, aiming to shorten experimental decision…
What a desert lizard teaches us about patents and the GLP-1 revolution
Dr. Eng patented the peptide. Amylin Pharmaceuticals eventually licensed and developed it into the first GLP-1 medicine. In 2005, the FDA approved it to treat type 2 diabetes. That 15-year journey — from discovery to drug approval —…
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity
Entrada Therapeutics (ENTR) Buy call: $8.50 fair value (~52% upside). Valuation is anchored by risk-adjusted pipeline estimates. See more details here. - Entrada Therapeutics is rated Buy with a $8.50 fair value, offering ~52% upside from…
Damora Therapeutics (DMRA) Climbed, So What Is Drawing Attention Now?
Damora Therapeutics (DMRA) traded at $21.08 at the last close, drawing fresh attention to how this biopharmaceutical player's hematology pipeline and financial profile intersect for long term investors. Scan how Damora Therapeutics…
Why Enliven Therapeutics' (ELVN) ENABLE-2 Trial Design Raises New Questions About Its CML Strategy
This progress clarifies the registrational pathway for Enliven's lead BCR::ABL1 inhibitor, including a statistically powered plan to show at least a 10‑percentage‑point improvement in major molecular response by Week 24 over current…
PolyPeptide Group (SWX:PPGN) Looks Fully Valued Following Samsung Biologics Tender Offer
UBS cut its rating on PolyPeptide Group (SWX:PPGN) to neutral after Samsung Biologics launched an all cash tender offer, shifting investor attention toward deal completion rather than potential new upside. At a share price of CHF43.85,…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com235
-
tradingview.com188
-
finance.yahoo.com156
-
seekingalpha.com85
-
biospace.com62
Measured across the 4GenX news index. Headline tone is a simple word-based reading of the latest 120 headlines, not a forecast.